> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Ratchets Up Heat on 7-OH Products
- URL: https://www.fdaweb.com/fda-ratchets-up-heat-on-7-oh-products/
- Published: 2025-07-29T12:00:00.000Z
- Updated: 2026-09-14T15:17:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159584

FDA is [recommending](https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers?utm%5Fmedium=email&utm%5Fsource=govdelivery) placing 7-hydroxymitragynine (7-OH) —a highly concentrated, synthetic byproduct of the kratom plant — under the Controlled Substances Act. The move marks a strategic crackdown on products the agency says are potent, addictive, and increasingly available in unregulated forms. Unlike natural kratom leaf, which is not currently targeted by this action, 7-OH binds to opioid receptors and has been shown to be more potent than morphine, raising serious concerns about its abuse potential. The agency notes that there are no approved medical uses for 7-OH and that it is not lawful as a dietary supplement or food additive.

In June, FDA issued warning letters to seven companies marketing illegal 7-OH products in various forms, including tablets, drink mixes, and shots. The agency also sent an alert to health care professionals and issued a new consumer advisory outlining the risks of 7-OH exposure.